Adverum Biotechnologies, Inc. Submits Form 3 Filing to SEC
Adverum Biotechnologies, Inc. (Issuer) has recently filed a Form 3 with the Securities and Exchange Commission (SEC), indicating significant changes in the ownership of the company’s securities. Form 3 is typically filed by individuals or entities who have recently become insiders of a company, such as directors, officers, or beneficial owners of more than 10% of a class of the company’s equity securities.
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company dedicated to developing novel gene therapies to treat patients with sight-threatening ocular diseases. The company’s innovative platform allows for the development of potentially transformative treatments for a range of inherited retinal diseases. For more information on Adverum Biotechnologies, Inc., please visit their website at https://www.adverum.com.
Form 3 filings provide investors and the public with transparency regarding changes in ownership of a company’s securities by insiders. This filing by Adverum Biotechnologies, Inc. signifies a notable event in the company’s corporate governance and ownership structure, which may impact its stock price and overall market perception. Investors and stakeholders should closely monitor such filings to stay informed about significant developments within the company.
Read More:
Adverum Biotechnologies, Inc. Submits Form 3 to the SEC – Learn More About the Filing
